Blinatumomab maintenance after stem cell transplant
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a drug called blinatumomab as a maintenance treatment to help keep your leukemia in remission after a stem cell transplant. It is for people with high-risk B-cell acute lymphoblastic leukemia who have already received a transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 16 to 65 years old
- Diagnosed with acute B-lymphoblastic leukemia that is CD19-positive
- Classified as high-risk leukemia
- Have a suitable stem cell donor for transplant
- No serious problems with your heart, liver, kidneys, or other vital organs
- Must be in remission and have no detectable cancer cells before starting this treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the drug blinatumomab for people whose B-cell acute lymphoblastic leukemia (B-ALL) has come back after a stem cell transplant. The goal is to see if blinatumomab can safely treat the relapse.
This trial tests a drug called blinatumomab, given after a stem cell transplant, to help prevent leukemia from coming back in people with high-risk B-cell acute lymphoblastic leukemia. It may help keep the cancer in remission for longer.
This study tests a drug called blinatumomab for people whose leukemia returns in a very early, hidden way after a stem cell transplant. The goal is to see if this drug can clear those leftover leukemia cells and help keep the disease from coming back.
This trial tests adding a drug called blinatumomab plus a low-dose donor lymphocyte infusion (DLI) as maintenance therapy after stem cell transplant for people with high-risk B-cell acute lymphoblastic leukemia (B-ALL). It aims to reduce the chance of the cancer coming back.
This trial tests blinatumomab, an immune therapy, in young people with B-cell acute lymphoblastic leukemia (B-ALL) after their transplant or when they are getting ready for transplant. The goal is to lower the chance of the leukemia coming back by targeting remaining leukemia cells.
This trial tests whether giving two drugs—blinatumomab (an immunotherapy) and donor lymphocyte infusions (white blood cells from your donor)—can help prevent leukemia from coming back after a stem cell transplant for high-risk B-ALL. It is for people who are in remission with no sign of leukemia cells.
Hear when a new High Risk Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.